Trending...
- Constant Contact Appoints Russ Morton as Chief Product Officer
- CreateTV.com's New Chefs' Indian and Cuban Recipes will Spice Up Your Meals!
- IntellaTriage Hires New Director of Clinical Operations
WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene today announced that four abstracts have been accepted for poster presentations for the 2022 San Antonio Breast Cancer Symposium (SABCS), which will be held December 6 - 9, 2022, at the Henry B. Gonzalez Convention Center in San Antonio, Texas. BostonGene will also exhibit at booth 107.
"The data we will present at SABCS demonstrates the clinical utility of BostonGene's AI-based molecular and immune profiling and analytics to advance and optimize outcomes for cancer patients," said Nathan Fowler, MD, Chief Medical Officer at BostonGene. "Our findings highlight the importance of a multifaceted approach to understand the composition and activity of the tumor and the microenvironment."
Details about the abstracts selected for presentation can be found below:
Abstract Number: 1304759
Title: A molecular classification system for basal-like breast cancer based on the tumor microenvironment is prognostic for survival
Date and Time: Thursday, December 8 | 7:00 AM - 8:15 AM
Location: Poster Session 4 – Hall 1
Poster Number: P4-09-02
Speaker: Nikita Kotlov, BostonGene
Using whole-transcriptome data clustering techniques, BostonGene uncovered five distinct basal-like breast cancer molecular functional portraits prognostic for survival using gene signatures from the tumor microenvironment.
Abstract Number: 1310282
Title: An HRD scoring system based on long-focal copy number alterations predictive of PARP inhibitor response
More on Boston Chron
Date and Time: Thursday, December 8 | 5:00 PM - 6:15 PM
Location: Poster Session 5 – Hall 1
Poster Number: P5-02-45
Speaker: Nikita Kotlov, BostonGene
BostonGene developed and validated a new homologous recombination deficiency (HRD) scoring system for breast cancer patients. This novel HRD score, which uses long-focal copy number alterations and ploidy rather than relying on germline mutations in the homologous recombination pathway, was predictive of PARP inhibitor response.
Abstract Number: 1310386
Title: AI-based prediction of tertiary lymphoid structures and lymphocyte immune infiltration in breast carcinomas
Date and Time: Friday, December 9 | 7:00 AM - 8:15 AM
Location: Poster Session 6 – Hall 1
Poster Number: P6-04-15
Speaker: Ekaterina Postovalova, PhD, BostonGene
Leveraging a convolutional neural network, BostonGene trained and validated an image analysis platform capable of detecting tertiary lymphoid structures and the lymphocyte immune-infiltrated area on breast carcinoma H&E slides. This AI-based approach may be used to automate the traditional pathology workflow.
Abstract Number: 1310481
Title: TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis.
Date and Time: Thursday, December 8 | 5:00 PM - 6:15 PM
Location: Poster Session 5 – Hall 1
Poster Number: P5-02-13
Speaker: Jennifer C. Keenan, Mass General Cancer Center
More on Boston Chron
In this case report, BostonGene's Tumor Portrait™ next-generation sequencing test provided orthogonal validation for two NTRK fusions, including one novel fusion, detected by cell-free DNA analysis in a metastatic triple-negative breast cancer patient.
Research conducted with Mass General Cancer Center
For more information, please visit the 2022 San Antonio Breast Cancer Symposium website. The abstracts will be published in the Abstracts2View™ online database at the conclusion of the symposium.
About BostonGene Corporation
BostonGene's mission is to power healthcare's transition to personalized medicine using our AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics. BostonGene Tumor Portrait™ Testsreveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene Tumor Portrait™ Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. For more information, visit BostonGene at http://www.BostonGene.com.
Contacts
Media:
BostonGene
Erin O'Reilly
+1-781-366-7049
Erin.Oreilly@BostonGene.com
"The data we will present at SABCS demonstrates the clinical utility of BostonGene's AI-based molecular and immune profiling and analytics to advance and optimize outcomes for cancer patients," said Nathan Fowler, MD, Chief Medical Officer at BostonGene. "Our findings highlight the importance of a multifaceted approach to understand the composition and activity of the tumor and the microenvironment."
Details about the abstracts selected for presentation can be found below:
Abstract Number: 1304759
Title: A molecular classification system for basal-like breast cancer based on the tumor microenvironment is prognostic for survival
Date and Time: Thursday, December 8 | 7:00 AM - 8:15 AM
Location: Poster Session 4 – Hall 1
Poster Number: P4-09-02
Speaker: Nikita Kotlov, BostonGene
Using whole-transcriptome data clustering techniques, BostonGene uncovered five distinct basal-like breast cancer molecular functional portraits prognostic for survival using gene signatures from the tumor microenvironment.
Abstract Number: 1310282
Title: An HRD scoring system based on long-focal copy number alterations predictive of PARP inhibitor response
More on Boston Chron
- Entrinsik Board Announces New CEO
- Work & Mother Announces Collaboration with Jamestown to Provide State-of-the-Art Lactation Suites in Select Commercial Buildings
- Knobull Streamlines Presentation Techniques That Turns Stress Into Enjoyment
- Eddie Turner Ranked #13 On The Power List Of The Top 200 Biggest Voices In Leadership In 2023
- The Data Economics Company and Gordian Knot Strategies Announce Enkrateia Climate Investment Decision Support Platform
Date and Time: Thursday, December 8 | 5:00 PM - 6:15 PM
Location: Poster Session 5 – Hall 1
Poster Number: P5-02-45
Speaker: Nikita Kotlov, BostonGene
BostonGene developed and validated a new homologous recombination deficiency (HRD) scoring system for breast cancer patients. This novel HRD score, which uses long-focal copy number alterations and ploidy rather than relying on germline mutations in the homologous recombination pathway, was predictive of PARP inhibitor response.
Abstract Number: 1310386
Title: AI-based prediction of tertiary lymphoid structures and lymphocyte immune infiltration in breast carcinomas
Date and Time: Friday, December 9 | 7:00 AM - 8:15 AM
Location: Poster Session 6 – Hall 1
Poster Number: P6-04-15
Speaker: Ekaterina Postovalova, PhD, BostonGene
Leveraging a convolutional neural network, BostonGene trained and validated an image analysis platform capable of detecting tertiary lymphoid structures and the lymphocyte immune-infiltrated area on breast carcinoma H&E slides. This AI-based approach may be used to automate the traditional pathology workflow.
Abstract Number: 1310481
Title: TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis.
Date and Time: Thursday, December 8 | 5:00 PM - 6:15 PM
Location: Poster Session 5 – Hall 1
Poster Number: P5-02-13
Speaker: Jennifer C. Keenan, Mass General Cancer Center
More on Boston Chron
- Best Pneumatic Air Jack for Cars (2023): VEVOR 5T Bag Air Jack Reviewed by Compare Before Buying
- Americana Songstress Emma Jo To Release Powerful New Single, 'Straight Into Mine'
- Bain Capital Specialty Finance, Inc. Schedules Earnings Release for the Fourth Quarter and Fiscal Year Ended December 31, 2022
- Boston: Mayor Michelle Wu, Superintendent Mary Skipper and Green New Deal Director Oliver Sellers-Garcia celebrate start of school bus fleet electrification
- IISE announces leadership election results
In this case report, BostonGene's Tumor Portrait™ next-generation sequencing test provided orthogonal validation for two NTRK fusions, including one novel fusion, detected by cell-free DNA analysis in a metastatic triple-negative breast cancer patient.
Research conducted with Mass General Cancer Center
For more information, please visit the 2022 San Antonio Breast Cancer Symposium website. The abstracts will be published in the Abstracts2View™ online database at the conclusion of the symposium.
About BostonGene Corporation
BostonGene's mission is to power healthcare's transition to personalized medicine using our AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics. BostonGene Tumor Portrait™ Testsreveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene Tumor Portrait™ Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. For more information, visit BostonGene at http://www.BostonGene.com.
Contacts
Media:
BostonGene
Erin O'Reilly
+1-781-366-7049
Erin.Oreilly@BostonGene.com
Filed Under: Business
0 Comments
Latest on Boston Chron
- Boston Celtics and Sun Life close out 9th annual Fit to Win youth program with Celtics forward Justin Jackson at trampoline park
- Boston: Fire Prevention Program Manager Certificate
- Boston: Mayor Wu Announces Members of Steering Committee to Advise on Reforms to Article 80 Development Review Process
- Dog Licensing Reminder (and Boston's Most Popular Dog Names!)
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Urban One Inc's Reach Media Announces R&B Superstar Ralph Tresvant of New Edition as Host of "Love and R&B"
- ABP Acquisition to Acquire AlerisLife for $1.31 Per Share
- Berkshire Hills Announces Quarterly Shareholder Dividend
- Louisville Riverport Authority Applies To Include South Central Kentucky In Foreign Trade Zone #29 Service Area
- Santander Bank Raises Its Prime Rate to 7.75%
- Constant Contact Appoints Russ Morton as Chief Product Officer
- IntellaTriage Hires New Director of Clinical Operations
- CyberSaint STRONGER 2023 Conference Call for Speakers is Open!
- Metro Commercial brokers deal for BJ's Wholesale Club in West Palm Beach, FL
- L-Strategies political and business consulting firm launched by partners Angie Wong and Jared Craig with Donna and Stan Fitzgerald
- UPS Launches Services at Neighborhood Parcel Authorized Shipping Center In Tewksbury MA
- Zilker Partners Expands Recruiting and Digital Marketing Services to Keep Pace with Changing Business Climate
- CreateTV.com's New Chefs' Indian and Cuban Recipes will Spice Up Your Meals!
- Dental Tourism is on the Rise and This Dental Hygienist is Providing the Consultations
- Sage Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023